Taysha Gene Therapies
TSHA
44 hedge funds and large institutions have $13.3M invested in Taysha Gene Therapies in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 13 closing their positions.
4.74% less ownership
Funds ownership: 31.03% → 26.3% (-4.7%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
15% less funds holding
Funds holding: 52 → 44 (-8)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
70% less capital invested
Capital invested by funds: $43.8M → $13.3M (-$30.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$185K |
| 2 |
Millennium Management
New York
|
+$117K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$112K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$110K |
| 5 |
Morgan Stanley
New York
|
+$82.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.65M |
| 2 |
ACM
Altium Capital Management
New York
|
-$811K |
| 3 |
BlackRock
New York
|
-$409K |
| 4 |
Renaissance Technologies
New York
|
-$349K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$256K |
TSHA Hedge Fund Activity: Q1 2023 in Review
44 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2023, worth a combined $13.3M — down 70% from $43.8M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TSHA and 5 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Acadian Asset Management, adding an estimated $185K. The largest seller was Nantahala Capital Management, cutting an estimated $1.65M.
- 44 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2023, down from 52 in Q4 2022.
- Funds reported $13.3M of Taysha Gene Therapies stock for Q1 2023, down 70% quarter-over-quarter.
- 5 funds opened new Taysha Gene Therapies positions in Q1 2023 and 13 closed out, a net change of -8 holders.
- The largest Taysha Gene Therapies buyer in Q1 2023 was Acadian Asset Management, an estimated $185K added.
- The largest Taysha Gene Therapies seller in Q1 2023 was Nantahala Capital Management, an estimated $1.65M sold.
Based on aggregated 13F filings for Q1 2023.